Equities
Health CarePharmaceuticals and Biotechnology
  • Price (USD)129.91
  • Today's Change-2.98 / -2.24%
  • Shares traded639.26k
  • 1 Year change+54.29%
  • Beta1.5078
Data delayed at least 15 minutes, as of Mar 03 2026 18:02 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Illumina, Inc. specializes in DNA sequencing and array-based technologies, serving customers in research, clinical and applied markets. The Company's products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. Its comprehensive line of products addresses the scale of experimentation and breadth of functional analysis to advance disease research, drug development, and the development of molecular tests. It also specializes in data-driven proteomics technology. Its products include instruments, kits and reagents, selection tools, and software and analysis. Its services include sequencing services, microarray services, proactive instrument monitoring, and instrument services and training.

  • Revenue in USD (TTM)4.34bn
  • Net income in USD850.00m
  • Incorporated2000
  • Employees8.60k
  • Location
    Illumina Inc5200 Illumina WaySAN DIEGO 92122United StatesUSA
  • Phone+1 (302) 658-7581
  • Fax+1 (302) 655-5049
  • Websitehttps://www.illumina.com
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
ILMN:NSQ since
announced
Transaction
value
Somalogic IncDeal completed23 Jun 202523 Jun 2025Deal completed43.56%425.00m
Data delayed at least 15 minutes, as of Mar 03 2026 18:02 GMT.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Guardant Health Inc982.02m-416.28m12.10bn2.49k------12.32-3.31-3.317.83-0.76020.56134.457.92394,385.90-23.79-25.70-28.02-28.9364.4663.20-42.39-76.304.56--1.07--32.8827.924.61---2.23--
Solventum Corp8.33bn1.56bn12.66bn20.00k8.232.516.191.528.878.8747.4829.100.57913.818.01416,250.0010.82--13.58--53.5756.9218.6915.050.89062.050.4993--0.86022.72224.846.466.94--
Globus Medical Inc2.94bn537.87m12.69bn6.00k23.842.7715.554.323.933.9321.4433.860.55691.354.75489,821.8010.196.1811.696.8967.4166.2018.3012.252.74--0.00020.0016.6530.08422.2839.3722.34--
Penumbra Inc1.40bn177.69m13.43bn4.70k75.689.4168.839.574.524.5235.7336.390.83561.107.85298,652.1010.584.0311.774.4967.1464.5712.665.394.29--0.01590.0017.5020.161,168.11--20.82--
Align Technology Inc4.03bn410.35m13.47bn20.29k33.403.3320.803.345.665.6655.5956.740.64835.333.85198,864.706.598.119.6711.9768.2770.6210.1712.311.24--0.000.000.89910.30-2.61-25.40-7.94--
Cooper Companies Inc4.09bn374.90m16.37bn15.00k44.792.0021.774.001.871.8720.4642.060.33121.715.29272,826.703.038.043.328.8665.5466.019.1624.661.136.320.23320.20495.0610.98-4.449.483.15--
Hologic Inc4.13bn543.80m16.84bn7.07k31.313.2120.074.082.412.4118.2823.510.46082.576.79583,663.406.0711.226.8212.8556.5160.2013.1821.993.3215.760.32460.001.741.66-28.35-12.69-0.5168--
Insulet Corp2.71bn247.10m17.28bn5.40k70.1211.4051.186.383.503.5037.8621.530.86281.746.14501,518.507.877.149.758.5171.6368.729.1310.062.1546.910.38520.0030.7324.53-40.93105.155.67--
West Pharmaceutical Services Inc3.07bn493.70m18.10bn10.80k36.985.7027.815.896.796.7942.2844.110.77694.805.40284,638.9012.1115.2414.2918.1935.9137.8915.5918.672.34--0.061410.136.257.440.2037.3610.395.51
Zimmer Biomet Holdings Inc8.23bn704.60m19.47bn17.00k28.061.5310.822.363.553.5541.4464.950.37031.105.17484,211.803.173.033.583.4669.7171.018.569.101.104.710.371829.267.206.08-21.98--9.260.00
Illumina Inc4.34bn850.00m20.32bn8.60k24.267.4718.144.685.485.4827.8817.800.67092.615.34505,000.0013.13-10.1517.32-12.1566.6165.3919.57-23.181.7215.790.4221---0.66336.04169.505.32-4.77--
Steris PLC5.83bn708.66m24.30bn17.79k34.483.4020.304.177.197.1859.0972.930.56584.926.12327,662.406.915.047.595.5144.1143.7512.2110.691.7520.990.209437.516.2412.4910.648.4011.528.99
DexCom Inc4.66bn836.30m28.40bn11.00k35.7110.3426.106.092.072.0711.507.140.7273.024.20423,818.2013.048.8521.5812.5862.0963.9217.9414.211.59--0.3204--15.6019.3345.148.7512.81--
Veeva Systems Inc3.08bn860.33m29.83bn7.29k35.294.2433.149.685.145.1418.4142.840.4234--9.15422,472.4011.8311.3313.5014.3575.6772.6027.9323.96----0.000.0016.2019.9935.8418.8536.56--
Data as of Mar 03 2026. Currency figures normalised to Illumina Inc's reporting currency: US Dollar USD

Institutional shareholders

49.24%Per cent of shares held by top holders
HolderShares% Held
Capital Research & Management Co. (World Investors)as of 31 Dec 202520.10m13.16%
BlackRock Fund Advisorsas of 31 Dec 202513.15m8.61%
The Vanguard Group, Inc.as of 31 Dec 202513.03m8.53%
SSgA Funds Management, Inc.as of 31 Dec 20256.19m4.05%
AQR Capital Management LLCas of 31 Dec 20254.43m2.90%
Loomis, Sayles & Co. LPas of 31 Dec 20254.17m2.73%
WCM Investment Management LLCas of 31 Dec 20254.07m2.66%
Corvex Management LPas of 31 Dec 20253.83m2.51%
Sessa Capital IM LPas of 31 Dec 20253.40m2.23%
Geode Capital Management LLCas of 31 Dec 20252.87m1.88%
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.